Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
25 Leser
Artikel bewerten:
(0)

Research and Markets - Global Intraosseous Infusion Devices Market to Grow at a CAGR of 4.67%, with BD, Cook Medical, Pyng Medical, PerSys Medical & Teleflex Dominating

DUBLIN, Mar 22, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Intraosseous Infusion Devices Market 2017-2021" report to their offering.

Research and Markets Logo

The global intraosseous infusion devices market to grow at a CAGR of 4.67% during the period 2017-2021.

One trend in the market is the growing use of intraosseous infusion devices in pediatric cases. The adoption of intraosseous infusion devices for interventions and therapies has increased considerably due to safety, rapid, and efficient fluid flow. The advances in intraosseous devices have allowed their use in pediatrics. For instance, the EZ-IO needle is available in different gauges for both pediatric and adult applications. Accessing the intravenous ROA in critically ill, injured infants, or young children is difficult or nearly impossible. This will delay the administration of critically needed medications or fluids. As the intraosseous ROA provides direct access to the marrow or medullary cavities in long bones, it is useful in gaining vascular access within minutes and is lifesaving. Intraosseous infusion devices are widely used as an alternative in severely hypovolemic children.

According to the report, one driver in the market is the increased incidence of chronic diseases leading to hospitalization. The sedentary lifestyle negatively affects the homeostasis of the body, making people susceptible to various disorders such as cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, end-stage renal disease, urology disorders, and other chronic illnesses.

According to multiple research studies, each year, about 970-990 million people worldwide have elevated blood pressure, of which 9.4-9.6 million deaths occur. Stroke causes 51% of these deaths, and the rest is caused by cardiac disorders. Diabetes causes greater complications with cardiovascular diseases. According to multiple research statistics, in 2015, more than 415 million adults aged 20-79 were affected by diabetes worldwide, including 193 million who were underdiagnosed, and the number is expected to reach 642 million by 2040.

Key vendors

  • BD
  • Cook Medical
  • Pyng Medical
  • PerSys Medical
  • Teleflex

Other prominent vendors

  • PAVmed
  • Biopsybell

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research methodology

PART 04: Introduction

PART 05: Intraosseous infusion device: An overview

PART 06: Market landscape

PART 07: Market segmentation by product type

PART 08: Market segmentation by end-user

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

PART 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/r3hq2r/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.